Clinically reviewed by Dr. Laura Purdy, MD, MBA · Last reviewed 2026-06-03

1. Assessment & candidacy

Every pathway begins with the oMeds Assessment. The assessment screens for symptom pattern, medical history, cardiovascular and thrombotic risk, fertility goals (where relevant), and current medications. Candidates whose context is incompatible with a given pathway are routed elsewhere or referred to appropriate care before any biomarker work is initiated.

2. Biomarker panel

The standardized oMeds biomarker panel covers Hormones, Lipids, CBC, and CMP. It is required at baseline and on the recalibration cadence for hormone optimization (TRT and BHRT). For NAD+, peptides, sexual wellness, hair, and metabolic pathways, the panel remains optional and is recommended but not required.

Read the full encyclopedia at /biomarkers.

3. Provider review (synchronous-only)

Every oMeds consultation is synchronous — live video with a licensed provider in the patient's state. There is no asynchronous prescribing. Provider review reads the assessment, the biomarker panel, and the patient's goals together and either initiates, adjusts, defers, or refers.

4. Dose, delivery & calibration

Dose and delivery modality (injectable, oral, topical, transdermal) are chosen by candidacy, biomarkers, and continuity preferences — not by patient request alone. The provider calibrates the starting point and defines the recalibration window (typically 8–12 weeks for hormone pathways).

5. Recalibration cadence

Longitudinal review is built into the membership rather than left to the patient to schedule. The biomarker panel is re-read at the recalibration window and on the ongoing cadence. Adjustments are provider-reviewed in synchronous video.

6. References & sources

Every biomarker, condition, comparison, and answer surface on oMeds cites its primary source. Reference ranges are drawn from named clinical laboratories (Quest, LabCorp, Mayo) and clinical guidelines (AHA/ACC, ATA, Endocrine Society, ESC). Editorial review and the reviewer attestation are visible on every surface.

7. Editorial governance

oMeds content is governed by a locked clinical vocabulary, a standardized authority spine, and a single reviewer of record. Every page surfaces the reviewer, the review date, and the next review window. Changes are tracked in the page revision metadata.